Advertisement

Rare Subentities of Urothelial Bladder Carcinoma

  • Bastian Keck
  • Simone Bertz
Living reference work entry

Abstract

Urothelial carcinomas harbor a propensity to divergent histologic differentiation with different clinical behavior and prognosis of the different histologic subtypes. The WHO classification therefore described a variety of distinct histologic variants of infiltrating urothelial carcinomas in 2016. Plasmacytoid urothelial carcinoma is characterized by a single-cell growth pattern that might be caused by loss of cell adhesion due to the lack of E-cadherin. Its clinical course is very aggressive with a high proportion of locally advanced disease and peritoneal spread. Micropapillary carcinomas respond poorly to intravesical BCG and progress rapidly to muscle invasive and metastatic disease, so that radical cystectomy with urinary diversion is regarded as the therapy of choice in this subtype. Nested-type and large nested urothelial carcinomas present tumor cells whose nuclei show only little or no atypia and are arranged in small nests. Treatment options do not differ from conventional urothelial carcinomas. Microcystic urothelial carcinoma shows round to oval microcysts and is a very rare and aggressive variant with hardly no survival of the cases described so far. Giant cell urothelial carcinoma is an extreme form of dedifferentiation with a bizarre and anaplastic appearance and frequent typical or atypical mitotic figures. Sarcomatoid urothelial carcinoma is characterized by spindle cells and has a very bad prognosis; however, it accounts only for a few cases. Lymphoepithelioma-like urothelial carcinoma which harbors a distinct lymphoid infiltrate including T and B lymphocytes, plasma cells, and differential diagnosis to exclude lymphoproliferative diseases is therefore very important in the clinical management.

References

  1. Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22:S96–S118.  https://doi.org/10.1038/modpathol.2009.26.CrossRefPubMedGoogle Scholar
  2. Amin MB, Ro JY, Lee KM, Ordonez NG, Dinney CP, Gulley ML, Ayala AG. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol. 1994;18(5):466–73.CrossRefGoogle Scholar
  3. Beltran AL, Cheng L, Montironi R, Blanca A, Leva M, Roupret M, Fonseca J, Vidal A, Menendez CL, Pallares J, Bollito E, Reymundo C, Luque RJ, Comperat E. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch. 2014;465(2):199–205.  https://doi.org/10.1007/s00428-014-1601-y.CrossRefPubMedGoogle Scholar
  4. Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rodel C, Fietkau R, Wullich B, Keck B, Hartmann A. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch. 2016;469(3):339–44.  https://doi.org/10.1007/s00428-016-1986-x.CrossRefPubMedGoogle Scholar
  5. Cockerill PA, Cheville JC, Boorjian SA, Blackburne A, Thapa P, Tarrell RF, Frank I. Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control. Urology. 2016;102:143.  https://doi.org/10.1016/j.urology.2016.09.053.CrossRefPubMedGoogle Scholar
  6. Comperat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaid I, Cussenot O, Samaratunga H. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology. 2010;42(7):650–4.  https://doi.org/10.3109/00313025.2010.522173.CrossRefPubMedGoogle Scholar
  7. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189(5):1656–61.  https://doi.org/10.1016/j.juro.2012.11.084.CrossRefPubMedGoogle Scholar
  8. Drew PA, Furman J, Civantos F, Murphy WM. The nested variant of transitional cell carcinoma: an aggressive neoplasm with innocuous histology. Mod Pathol. 1996;9(10):989–94.PubMedGoogle Scholar
  9. Fatima N, Osunkoya AO. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder. Hum Pathol. 2014;45(8):1625–9.  https://doi.org/10.1016/j.humpath.2014.03.015.CrossRefPubMedGoogle Scholar
  10. Fukunaga M, Ushigome S. Lymphoepithelioma-like carcinoma of the renal pelvis: a case report with immunohistochemical analysis and in situ hybridization for the Epstein-Barr viral genome. Mod Pathol. 1998;11(12): 1252–6.PubMedGoogle Scholar
  11. Goto K. CD138 expression is observed in the urothelial epithelium and in various urothelial carcinomas, and cannot be evidence for plasmacytoid urothelial carcinoma. Int J Surg Pathol. 2016;24(7):614–9.  https://doi.org/10.1177/1066896916653673.CrossRefPubMedGoogle Scholar
  12. Gulley ML, Amin MB, Nicholls JM, Banks PM, Ayala AG, Srigley JR, Eagan PA, Ro JY. Epstein-Barr virus is detected in undifferentiated nasopharyngeal carcinoma but not in lymphoepithelioma-like carcinoma of the urinary bladder. Hum Pathol. 1995;26(11):1207–14.CrossRefGoogle Scholar
  13. Holmang S, Borghede G, Johansson SL. Bladder carcinoma with lymphoepithelioma-like differentiation: a report of 9 cases. J Urol. 1998;159(3):779–82.CrossRefGoogle Scholar
  14. Ikegami H, Iwasaki H, Ohjimi Y, Takeuchi T, Ariyoshi A, Kikuchi M. Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol. 2000;31(3): 332–40.CrossRefGoogle Scholar
  15. James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA, Investigators BC. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.  https://doi.org/10.1056/NEJMoa1106106.CrossRefPubMedGoogle Scholar
  16. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007;110(1):62–7.  https://doi.org/10.1002/cncr.22756.CrossRefPubMedGoogle Scholar
  17. Keck B, Stoehr R, Wach S, Rogler A, Hofstaedter F, Lehmann J, Montironi R, Sibonye M, Fritsche HM, Lopez-Beltran A, Epstein JI, Wullich B, Hartmann A. The plasmacytoid carcinoma of the bladder – rare variant of aggressive urothelial carcinoma. Int J Cancer. 2011;129(2):346–54.  https://doi.org/10.1002/ijc.25700.CrossRefPubMedGoogle Scholar
  18. Keck B, Wach S, Kunath F, Bertz S, Taubert H, Lehmann J, Stockle M, Wullich B, Hartmann A. Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder. Ann Surg Oncol. 2013a;20(7):2440–5.  https://doi.org/10.1245/s10434-012-2709-4.CrossRefPubMedGoogle Scholar
  19. Keck B, Wach S, Stoehr R, Kunath F, Bertz S, Lehmann J, Stockle M, Taubert H, Wullich B, Hartmann A. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer. 2013b;13:71.  https://doi.org/10.1186/1471-2407-13-71.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Kotliar SN, Wood CG, Schaeffer AJ, Oyasu R. Transitional cell carcinoma exhibiting clear cell features. A differential diagnosis for clear cell adenocarcinoma of the urinary tract. Arch Pathol Lab Med. 1995;119(1): 79–81.PubMedGoogle Scholar
  21. Krause FS, Walter B, Ott OJ, Haberle L, Weiss C, Rodel C, Wullich B, Sauer R. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011;31(3):985–90.PubMedGoogle Scholar
  22. Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014;142(6):864–71.  https://doi.org/10.1309/AJCP1J0JPJBPSUXF.CrossRefPubMedGoogle Scholar
  23. Lopez-Beltran A, Escudero AL, Cavazzana AO, Spagnoli LG, Vicioso-Recio L. Sarcomatoid transitional cell carcinoma of the renal pelvis. A report of five cases with clinical, pathological, immunohistochemical and DNA ploidy analysis. Pathol Res Pract. 1996;192(12):1218–24.  https://doi.org/10.1016/S0344-0338(96)80154-3.CrossRefPubMedGoogle Scholar
  24. Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG. Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol. 1998;159(5): 1497–503.  https://doi.org/10.1097/00005392-199805000-00023.CrossRefPubMedGoogle Scholar
  25. Lopez-Beltran A, Luque RJ, Vicioso L, Anglada F, Requena MJ, Quintero A, Montironi R. Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Arch. 2001;438(6):552–7.CrossRefGoogle Scholar
  26. Lopez-Beltran A, Requena MJ, Montironi R, Blanca A, Cheng L. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009a;40(7):1023–8.  https://doi.org/10.1016/j.humpath.2009.01.001.CrossRefPubMedGoogle Scholar
  27. Lopez-Beltran A, Blanca A, Montironi R, Cheng L, Regueiro JC. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009b;40(10):1461–6.  https://doi.org/10.1016/j.humpath.2009.02.016.CrossRefPubMedGoogle Scholar
  28. Mai KT, Bateman J, Djordjevic B, Flood TA, Belanger EC. Clear cell urothelial carcinoma: a study of 10 cases and meta-analysis of the entity. Evidence of mesonephric differentiation. Int J Surg Pathol. 2016;25:18.  https://doi.org/10.1177/1066896916660195.CrossRefPubMedGoogle Scholar
  29. Masson-Lecomte A, Xylinas E, Bouquot M, Sibony M, Allory Y, Comperat E, Zerbib M, de la Taille A, Roupret M. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World J Urol. 2015;33(8): 1087–93.  https://doi.org/10.1007/s00345-014-1387-1.CrossRefPubMedGoogle Scholar
  30. Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors. Who classification of tumors of the urinary system and male genital organs. 4th ed. Lyon: IARC; 2016.Google Scholar
  31. Murphy WM, Deana DG. The nested variant of transitional cell carcinoma: a neoplasm resembling proliferation of Brunn’s nests. Mod Pathol. 1992;5(3):240–3.PubMedGoogle Scholar
  32. Paner GP, Annaiah C, Gulmann C, Rao P, Ro JY, Hansel DE, Shen SS, Lopez-Beltran A, Aron M, Luthringer DJ, De Peralta-Venturina M, Cho Y, Amin MB. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. Hum Pathol. 2014;45(7):1473–82.  https://doi.org/10.1016/j.humpath.2014.02.024.CrossRefPubMedGoogle Scholar
  33. Paz A, Rath-Wolfson L, Lask D, Koren R, Manes A, Mukamel E, Gal R. The clinical and histological features of transitional cell carcinoma of the bladder with microcysts: analysis of 12 cases. Br J Urol. 1997;79(5): 722–5.CrossRefGoogle Scholar
  34. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37.  https://doi.org/10.1016/j.eururo.2014.02.038.CrossRefPubMedGoogle Scholar
  35. Reuter VE. Sarcomatoid lesions of the urogenital tract. Semin Diagn Pathol. 1993;10(2):188–201.PubMedGoogle Scholar
  36. Ricardo-Gonzalez RR, Nguyen M, Gokden N, Sangoi AR, Presti JC Jr, McKenney JK. Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J Urol. 2012;187(3):852–5.  https://doi.org/10.1016/j.juro.2011.10.145.CrossRefPubMedGoogle Scholar
  37. Samaratunga H, Delahunt B. Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology. 2012;44(5):407–18.  https://doi.org/10.1097/PAT.0b013e3283560172.CrossRefPubMedGoogle Scholar
  38. Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Ferguson P, Nacey JN. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation. Histopathology. 2016;68(4): 533–40.  https://doi.org/10.1111/his.12785.CrossRefPubMedGoogle Scholar
  39. Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE. Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition. Arch Pathol Lab Med. 2016;140(6):543–51.  https://doi.org/10.5858/arpa.2015-0085-OA.CrossRefPubMedGoogle Scholar
  40. Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014;27(5):758–64.  https://doi.org/10.1038/modpathol.2013.201.CrossRefPubMedGoogle Scholar
  41. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–5; discussion 475–467.  https://doi.org/10.1016/j.eururo.2005.12.031.CrossRefPubMedGoogle Scholar
  42. Tamas EF, Nielsen ME, Schoenberg MP, Epstein JI. Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol. 2007;20(8):828–34.  https://doi.org/10.1038/modpathol.3800823.CrossRefPubMedGoogle Scholar
  43. Venyo AK. Microcystic variant of urothelial carcinoma. Adv Urol. 2013;2013:654751.  https://doi.org/10.1155/2013/654751.CrossRefPubMedPubMedCentralGoogle Scholar
  44. Wang J, Wang FW, Lagrange CA, Hemstreet Iii GP, Kessinger A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma. 2010;2010.  https://doi.org/10.1155/2010/454792.CrossRefGoogle Scholar
  45. Yamashita R, Yamaguchi R, Yuen K, Niwakawa M, Tobisu K. Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain. Int J Urol. 2006;13(11):1448–50.  https://doi.org/10.1111/j.1442-2042.2006.01569.x.CrossRefPubMedGoogle Scholar
  46. Zhong M, Tian W, Zhuge J, Zheng X, Huang T, Cai D, Zhang D, Yang XJ, Argani P, Fallon JT, Epstein JI. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol. 2015;39(1):127–31.  https://doi.org/10.1097/PAS.0000000000000305.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Private Practice of UrologyErlangenGermany
  2. 2.Department of UrologyBridge Consortium e.V.MannheimGermany
  3. 3.Department of PathologyUniversity Hospital ErlangenErlangenGermany

Section editors and affiliations

  • Wolfgang Otto
    • 1
  • Shahrokh F. Shariat
    • 2
  1. 1.Department of UrologyUniversity of RegensburgRegensburgGermany
  2. 2.Departement of UrologyWeill Cornell Medical CenterNew YorkUSA

Personalised recommendations